The 10-second takeaway
For the quarter ended March 31 (Q1), Pacira Pharmaceuticals whiffed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. GAAP loss per share increased.
Margins dropped across the board.
Pacira Pharmaceuticals recorded revenue of $11.6 million. The four analysts polled by S&P Capital IQ wanted to see net sales of $13.2 million on the same basis. GAAP reported sales were 48% higher than the prior-year quarter's $7.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.71. The five earnings estimates compiled by S&P Capital IQ predicted -$0.42 per share. GAAP EPS were -$0.71 for Q1 compared to -$0.47 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 1.7%, much worse than the prior-year quarter. Operating margin was -160.9%, much worse than the prior-year quarter. Net margin was -199.7%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $16.6 million. On the bottom line, the average EPS estimate is -$0.33.
Next year's average estimate for revenue is $74.6 million. The average EPS estimate is -$1.22.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 22 members out of 33 rating the stock outperform, and 11 members rating it underperform. Among seven CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give Pacira Pharmaceuticals a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $31.60.
- Add Pacira Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much as 24%
Despite a mixed third-quarter report, Pacira topped Wall Street's expectations where it counts.
Why Pacira Pharmaceuticals Shares Are Crashing 15% Today
Disappointing late-stage trial data is dashing investor optimism.
4 Small-Cap Stocks Set to Grow EPS by at Least 400% Through 2020
You'd struggle to find faster-growing small-cap stocks.